Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.
D000368:Aged; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001479:Basal Ganglia / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry; D002421:Caudate Nucleus / Q000378:metabolism; D002525:Cerebellar Cortex / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000378:metabolism*; D010165:Palladium / Q000378:metabolism; D010300:Parkinson Disease / Q000378:metabolism* / Q000473:pathology; D010648:Phenylacetates / Q000378:metabolism; D013378:Substantia Nigra / Q000378:metabolism; D013788:Thalamus / Q000378:metabolism
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D010648:Phenylacetates; D010165:Palladium; D004295:Dihydroxyphenylalanine; D004298:Dopamine; D009638:Norepinephrine